SIREN : 505251355
OLEA MEDICAL is a French company founded 17 years ago, specialized in the sector Edition de logiciels applicatifs. Based in LA CIOTAT (13600), this company of category ETI shows in 2024 a revenue of 9.5 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 9 471 639 € | 12 659 714 € | 9 740 370 € | 9 541 214 € | 7 597 705 € | 11 290 124 € | 7 622 971 € | 4 067 608 € |
| Net income | 76 604 € | 787 293 € | -2 810 101 € | 260 476 € | -1 609 765 € | 336 906 € | -606 138 € | -2 846 207 € |
| EBITDA | -321 338 € | 2 103 336 € | -1 221 876 € | 75 561 € | -1 901 958 € | 1 701 220 € | 709 922 € | -3 625 871 € |
| Net margin | 0.8% | 6.2% | -28.9% | 2.7% | -21.2% | 3.0% | -8.0% | -70.0% |
In 2024, OLEA MEDICAL achieves revenue of 9.5 M€. Over the period 2017-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +12.8%. Significant drop of -25% vs 2023. After deducting consumption (0 €), gross margin stands at 9.5 M€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches -321 k€, representing -3.4% of revenue. Warning negative scissor effect: despite revenue change (-25%), EBITDA varies by -115%, reducing margin by 20.0 pts. This reflects costs rising faster than revenue. Negative EBITDA means operations do not cover current expenses: concerning situation. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 77 k€, i.e. 0.8% of revenue. This profit can be retained or distributed to shareholders.
9 471 639 €
9 471 639 €
-321 338 €
-1 498 749 €
76 604 €
-3.4%
The debt ratio (= Financial debt / Equity x 100) stands at 956%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 9%. Low autonomy: the company heavily depends on external financing (banks, suppliers). Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 26.3 years of cash flow to repay all financial debt. Beyond 7 years, banks generally consider credit risk as high. Cash flow represents 11.4% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
956.273%
8.903%
11.411%
26.264
16.7%
In 2024, the debt ratio of OLEA MEDICAL (956.27) ranks in the top 25% of the sector. This ratio measures the weight of debt relative to equity. A high ratio may indicate excessive dependence on external financing.
In 2024, the financial autonomy of OLEA MEDICAL (8.9%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2024, the repayment capacity of OLEA MEDICAL (26.26) ranks in the top 25% of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A long duration may signal heavy debt relative to repayment capacity.
The liquidity ratio (= Current assets / Current liabilities) stands at 705.85. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
705.845
-369.422
In 2024, the liquidity ratio of OLEA MEDICAL (705.85) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
In 2024, the interest coverage of OLEA MEDICAL (-369.4x) ranks in the bottom 25% of the sector. This ratio indicates how many times operating income covers interest expenses. Low coverage may indicate fragility to rate or income variations.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 49 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 31 days. The company must finance 18 days of gap between collections and payments. Overall, WCR represents 337 days of revenue, i.e. 8.9 M€ to permanently finance. Over 2017-2024, WCR increased by +280%, requiring additional financing.
8 862 707 €
49 j
31 j
0 j
337 j
Based on 103 transactions of similar company sales (all years), the value of OLEA MEDICAL is estimated at 1 451 352 € (range 638 590€ - 3 235 701€). The price/revenue ratio is 0.25x (conservative valuation). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 103 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare OLEA MEDICAL with other companies in the same sector:
Voir toutes les statistiques du secteur Edition de logiciels applicatifs
The revenue of OLEA MEDICAL in 2024 is 9.5 M€.
Yes, OLEA MEDICAL generated a net profit of 77 k€ in 2024.
The headquarters of OLEA MEDICAL is located in LA CIOTAT (13600), in the department Bouches-du-Rhone.
The tax return of OLEA MEDICAL is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
OLEA MEDICAL operates in the sector Edition de logiciels applicatifs (NAF code 58.29C). See the 'Sector positioning' section above to compare the company with its competitors.